This study indicated that when NGS testing was employed for prognostic risk stratification in thyroid cancer, the use of small panels targeting key prognostic loci (such as TERTp, PIK3CA, TP53, AKT1, etc.)offered comparable efficiency in risk grouping. This evidence concerns the gene TP53 and thyroid cancer.